Zenas BioPharma (NASDAQ:ZBIO) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of Zenas BioPharma (NASDAQ:ZBIO) from a hold rating to a strong sell rating in a research report report published on Tuesday morning,Zacks.com reports.

ZBIO has been the topic of several other reports. Citigroup cut their target price on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday. Wedbush restated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $44.00 target price on shares of Zenas BioPharma in a research note on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Zenas BioPharma presently has an average rating of “Hold” and a consensus price target of $44.14.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $23.03 on Tuesday. The stock has a market cap of $1.32 billion, a PE ratio of -2.95 and a beta of -1.94. The stock has a 50-day moving average of $22.91 and a 200-day moving average of $27.15. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.66. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity

In related news, Director Hongbo Lu acquired 25,985 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were acquired at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the acquisition, the director directly owned 347,968 shares in the company, valued at approximately $7,829,280. The trade was a 8.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was bought at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the completion of the transaction, the chief executive officer directly owned 423,155 shares in the company, valued at $7,599,863.80. This represents a 15.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 202,845 shares of company stock worth $3,747,185 over the last quarter. 16.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zenas BioPharma

A number of large investors have recently added to or reduced their stakes in ZBIO. Quarry LP raised its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter worth about $30,000. GF Fund Management CO. LTD. acquired a new position in shares of Zenas BioPharma during the fourth quarter worth about $38,000. BNP Paribas Financial Markets grew its holdings in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after buying an additional 1,716 shares in the last quarter. Finally, CWM LLC grew its holdings in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares in the last quarter.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company says funding supports continued development of obexelimab — a key clinical program that underpins long‑term value, which helps stabilize investor confidence. Zenas BioPharma Funding Supports Obexelimab Plans
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and kept a $44 price target, signaling strong upside from some sell‑side analysts and supporting bullish expectations. HC Wainwright Rating
• Neutral Sentiment: Citigroup trimmed its price target from $43 to $41 but maintained a “buy” rating — a modest downgrade to upside assumptions but not a change in overall endorsement. Citigroup Price Target Cut
• Neutral Sentiment: Morgan Stanley raised its target to $21 and kept an “equal weight”/Hold stance, reflecting a balanced near‑term view that recognizes pipeline potential but flags commercial and leverage uncertainties. Morgan Stanley / TipRanks Note
• Negative Sentiment: Quarterly results missed materially — Zenas reported EPS of ($4.54) vs. consensus of ($1.22). The magnitude of the miss increases short‑term downside risk and raises questions about near‑term cash burn and execution. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action introduces additional financial and operational risk, which can pressure the stock while litigation remains unresolved. IPO-Related Class Action

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.